Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study.

ABSTRACT:

Purpose

To measure the frequency of prescription medication changes following direct-to-consumer personal genomic testing (DTC-PGT) and their association with the pharmacogenomic results received.

Methods

New DTC-PGT customers were enrolled in 2012 and completed surveys prior to the return of results and 6 months after results; DTC-PGT results were linked to survey data. "Atypical response" pharmacogenomic results were defined as those indicating an increase or decrease in risk of an adverse drug event or likelihood of therapeutic benefit. At follow-up, participants reported prescription medication changes and health-care provider consultation.

Results

Follow-up data were available from 961 participants, of whom 54 (5.6%) reported changing a medication they were takin

SUBMITTER: Carere DA 

PROVIDER: S-EPMC5362351 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature